news

Scientists control living cells using artificial protein switch

Posted: 24 July 2019 | | No comments yet

Scientists have created the first completely artificial protein switch that can be ‘programmed’ to modify gene expression.

LOCKR is a molecular switch made of multiple interacting parts: a 'key' (black) unlocks a 'cage' (grey), revealing a bioactive peptide (yellow) which can interact with other molecules in the cell. LOCKR, a synthetic protein complex, was computationally designed from scratch, then tested in living cells (credit: Ian Haydon, UW Medicine Institute for Protein Design).

Scientists have created the first completely artificial protein switch (dubbed LOCKR – Latching, Orthogonal Cage/Key pRotein) that can work inside living cells to modify – or even commandeer – the cell’s complex internal circuitry. According to the developers, the switch could enable a new wave of therapies for diseases as diverse as cancer, autoimmune disorders and more.

…the switch could enable a new wave of therapies for diseases as diverse as cancer, autoimmune disorders and more

The scientists show in their research reports that LOCKR can be ‘programmed’ to modify gene expression, redirect cellular traffic, degrade specific proteins, and control protein binding interactions. They have also used LOCKR to build new biological circuits that behave like autonomous sensors. These circuits detect cues from the cell’s environment and respond by making changes to the cell. Once assembled by a cell, these new switches measure just eight nanometers on their longest side. 

“The ability to control cells with designer proteins ushers in a new era of biology,” said Hana El-Samad, the Kuo Family Professor of Biochemistry and Biophysics at the University of San Francisco (UCSF) and co-senior author of the reports. “In the same way that integrated circuits enabled the explosion of the computer chip industry, these versatile and dynamic biological switches could soon unlock precise control over the behaviour of living cells and ultimately, our health.”

 

Reserve your FREE place

 


Are you looking to optimise antibody leads in your drug discovery? Register for this webinar to find out how!

30 July 2025 | 10:00 AM BST | FREE Webinar

Join this webinar to hear from Dr. Lei Guo as she shares how early insights into liability, PK, stability, and manufacturability can help you optimise antibody leads in early drug discovery – and mitigate downstream risks later in development.

What You’ll Learn:

  • How to assess key developability risks early
  • How in silico modelling and in vitro testing can be combined to predict CMC risks earlier in discovery stage
  • How micro-developability strategies are tailored for complex or novel formats

Don’t miss your chance to learn from real-world leaders

Register Now – It’s Free!

 

“Right now, every cell is responding to its environment,” added one of the lead authors of the study, Bobby Langan, from the University of Washington Medicine Institute for Protein Design. “Cells receive stimuli, then have to figure out what to do about it. They use natural systems to tune gene expression or degrade proteins, for example.”

The scientists set out to create a new way to interface with these cellular systems. They used computational protein design to create self-assembling proteins that present bioactive peptides only upon addition of specific molecular “keys”.

With a version of LOCKR installed in yeast, the team was able to show that the genetically engineered fungus could be made to degrade a specific cellular protein at a time of their choosing. By redesigning the switch, they also demonstrated the same effect in lab-grown human cells.

The companion papers to this study were published in the journal Nature.

Leave a Reply

Your email address will not be published. Required fields are marked *